Patent 7524848 was granted and assigned to Amgen on April, 2009 by the United States Patent and Trademark Office.
Diaza heterocyclic amide derivatives according to Formula (I) have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: